Adjuvant olaparib has recently been shown to have a greater overall survival( OS ) benefit than placebo in patients with early breast cancer and BRCA1 / BRCA2 mutations, according to the OlympiA trial. Patients with triple-negative breast cancer ( TNBC ), which is characterized by the absence of estrogen, progesterone, and human epidermal growth factor receptor 2 ( HER2 ) expression, which accounts for 15 % of breast tumors, were enrolled in 1 OlympiA study.